Isabelle De Walsche – Managing Director, Gedeon Richter BeNeLux
Isabelle De Walsche, managing director of Gedeon Richter in Belgium, the Netherlands, and Luxembourg gives an…
Address: Gyömrői út 19-21, H-1103 Budapest, Hungary,Hungary
Tel: (+36) 1-431-4000
Web: http://www.richter.hu/HU/Pages/home.aspx
Gedeon Richter Plc. is a Hungarian-controlled Central-Eastern European multinational pharmaceutical company. The parent company and its manufacturing subsidiaries in four countries combine to form the region’s leading pharmaceutical manufacturing group. The Company’s products are available, through its own distribution network, to the inhabitants of some 100 different countries.
Our activity includes research, development, manufacture and marketing of human finished drugs, active substances and intermediates.
Isabelle De Walsche, managing director of Gedeon Richter in Belgium, the Netherlands, and Luxembourg gives an…
With a footprint of over 20 years in the Czech Republic, Gedeon Richter’s affiliate here is a key pillar to the…
Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company’s performance, its…
Andras Gizur, president China & APAC for Gedeon Richter, shares his insights on the current market environment…
Emmanuel Eumont, general manager of Gedeon Richter France, discusses the group’s leading position in women’s…
Corina Croitoru of Gedeon Richter Slovakia discusses GR’s footprint in the country, the affiliate’s main growth…
Country Manager Giovanna Labbate talks how Gedeon Richter aims to become the point of reference for women’s…
Isabelle de Walsche, Managing Director of Gedeon Richter Benelux, provides us with an update on the development of…
The president of Gedeon Richter France and CEO of PregLem, a Swiss-based biotech company acquired by Gedeon Richter…
Mr. Gyürüsi, Gedeon Richter is a 111-year-old company that is synonymous with the Central and Eastern…
Since establishing Gedeon Richter’s operations here 16 years ago, you’ve been involved in the full…
Gedeon Richter’s Erik Bogsch discusses the company’s 100th anniversary, it’s growing…
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai…
Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of…
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the…
The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and…
One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River…
HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T:…
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi…
Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact…
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug…
2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being…
Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of…